Oncopeptides

Oncopeptides is a pharmaceutical company dedicated to developing targeted therapies for refractory hematological diseases. The company focuses on developing its lead candidate drug, Melflufen, a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.